Aastrom Biosciences, Inc. (Nasdaq:ASTM) announced that the first patient has been enrolled in the REVIVE Phase 3 clinical trial of ixmyelocel-T in the treatment of critical limb ischemia (CLI).
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) said that it expects to submit a sNDA during mid-2012 seeking priority review of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic non-cancer pain
OXiGENE, Inc. (Nasdaq: OXGN) said in its earnings release that it hopes to initiate its FACT 2, Phase 3 trial of ZYBRESTAT in patients with anaplastic thyroid cancer, during 4Q 2012.
Resverlogix Corp. (TSX:RVX) announced that dosing in its Phase 2b trial (SUSTAIN) of RVX-208 has been completed. Top line data are due in Q3 2012, while data from its Phase 3 ASSURE trial are due in Q1 2013.
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) said that it expects to complete its Phase 2 study of IMO-3100 in patients with psoriasis during 1H 2013.
ARIAD Pharmaceuticals, Inc.(NASDAQ: ARIA) reported financial results for the latest quarter and noted that both NDA and MAA filings are expected in 3Q 2012 for ponatinib, in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL). In addition a Phase 3 trial of ponatinib in patients with newly diagnosed CML is also scheduled to start in the 3Q 2012. A Phase 2 trial of ponatinib in newly diagnosed patients with CML is now enrolling, while a Phase 2 trial in patients with Ph+ALL is also ongoing. Its Phase 2 trial in patients with CML who have failed imatinib is in advanced planning. The company also noted that it expects to move into the Phase 2 portion of its Phase 1/2 trial at approximately mid-year 2012 in its trial of AP26113 in ALK-positive and EGFR-positive lung cancer patients.